Targeting COX-2/PG-E2 with a COX-2 inhibitor in combination with chemotherapy for non-small cell lung cancer: are we ready for phase III?
Aisner
Joseph
J
Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, and the Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA. aisnerjo@umdnj.edu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000503:physiopathology; D017326:Clinical Trials, Phase III as Topic; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D015232:Dinoprostone / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000502:physiology*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
D016861:Cyclooxygenase Inhibitors; D015232:Dinoprostone